Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Herestraat, ON 1/902, 3000 Leuven, Belgium.
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) & Unidad de Gestión Clínica (UGC) de Endocrinología y Nutrición, Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
J Steroid Biochem Mol Biol. 2023 Apr;228:106248. doi: 10.1016/j.jsbmb.2023.106248. Epub 2023 Jan 13.
Vitamin D deficiency remains prevalent, with about 7% of the world's population living with severe vitamin D deficiency and about one third with mild deficiency. We compare the relative merits of calcifediol or 25-hydroxyvitamin D (25OHD) compared to vitamin D itself for supplementation as to prevent or cure vitamin D deficiency. The intestinal absorption of calcifediol is nearly 100% and thus higher than that of vitamin D itself. Moreover, calcifediol is absorbed by the intestinal cells and transported through the portal vein and thus immediately accessible to the circulation, while vitamin D is transported with chylomicrons through the lymph system. Therefore, in case of fat malabsorption or after bariatric surgery, calcifediol is much better absorbed in comparison with vitamin D itself. Serum 25OHD increases linearly with increasing doses of calcifediol, whereas serum 25OHD reaches a plateau when higher oral doses of vitamin D are used. Calcifediol, on a weight basis, is about 3 times more potent than vitamin D in subjects with mild vitamin D deficiency. This potency is even 6-8 times higher than vitamin D when baseline serum 25OHD is higher or when large doses are compared. In conclusion, calcifediol is an alternative option to correct vitamin D deficiency and may even be the preferred strategy in case of intestinal fat malabsorption, after bariatric surgery or in case of other conditions with suspected impaired 25-hydroxylase activity in the liver.
维生素 D 缺乏仍然很普遍,全世界约有 7%的人口患有严重的维生素 D 缺乏症,约三分之一的人患有轻度缺乏症。我们比较了 calcifediol 或 25-羟维生素 D(25OHD)与维生素 D 本身作为补充剂的相对优点,以预防或治疗维生素 D 缺乏症。calcifediol 的肠吸收率接近 100%,因此高于维生素 D 本身。此外,calcifediol 被肠细胞吸收,并通过门静脉运输,因此立即可进入循环,而维生素 D 则与乳糜微粒一起通过淋巴系统运输。因此,在脂肪吸收不良或减肥手术后,与维生素 D 本身相比,calcifediol 的吸收要好得多。血清 25OHD 随 calcifediol 剂量的增加呈线性增加,而当使用较高的口服维生素 D 剂量时,血清 25OHD 达到平台期。以体重为基础,calcifediol 在轻度维生素 D 缺乏症患者中的效力比维生素 D 大约高 3 倍。当基线血清 25OHD 较高或比较大剂量时,这种效力甚至比维生素 D 高 6-8 倍。总之,calcifediol 是纠正维生素 D 缺乏的一种替代选择,在肠脂肪吸收不良、减肥手术后或其他疑似肝脏 25-羟化酶活性受损的情况下,它甚至可能是首选策略。